Surgery, Gastroenterology and Oncology
Vol. 23, No. 4, Aug 2018
Surgical Outcome of Extra-hepatic Cholangiocarcinoma
Michiaki Unno, Kei Nakagawa, Hiroki Hayashi, Koji Fukase, Fuyuhiko Motoi, Takashi Kamei, Takeshi Naitoh
ORIGINAL PAPER, Aug 2018
Article DOI: 10.21614/sgo-23-4-278
Extrahepatic cholangiocarcinoma is divided into two compartments, namely perihilar cholangiocarcinoma and distal cholangiocarcinoma. Hemihepatectomy and caudate lobectomy with resection of extrahepatic bile duct is usually performed for patients with perihilar cholangiocarcinoma, whereas pancreaticoduodenectomy is performed for distal cholangiocarcinoma.
As pancreaticoduodenectomy has been a well-established and more commonly performed operation, distal cholangiocarcinoma was thought to have better outcomes as compared to perihilar cholangiocarcinoma. However, both cholangiocarcinomas originate from the bile duct epithelium and it is not clear if the malignant potential of perihilar cholangiocarcinoma and distal cholangiocarcinoma are different or not. Therefore, we analyzed 162 perihilar and 98 distal cholangiocarcinoma in our institution from 2002 to 2011, to clarify the actual overall survival, disease-free survival, and prognostic factors.
The actual 5-year overall survivals of perihilar and distal cholangiocarcinoma were 39.8 % and 45.2%, respectively, and actual 5-year disease-free survivals were 29.6% and 38.4%, respectively. There are no significant differences in overall survival and disease-free survival between perihilar and distal cholangiocarcinoma.
In both cholangiocarcinomas groups independent prognostic factors were distant metastasis, lymph node metastases, perineural invasion, and lack of R0 resection. In conclusion, the oncological outcomes of perihilar and distal cholangiocarcinoma are similar poor long-term outcome for both groups. Effective neoadjuvant and adjuvant therapies must be established to improve patients prognosis.

Full Text Sources: Download pdf
Abstract:   Abstract EN
Views: 3130


Watch Video Articles


For Authors



Journal Subscriptions

Current Issue

Dec 2025

Supplements

Instructions for authors
Online submission
Contact
ISSN: 2559 - 723X (print)

e-ISSN: 2601 - 1700 (online)

ISSN-L: 2559 - 723X

Journal Abbreviation: Surg. Gastroenterol. Oncol.

Surgery, Gastroenterology and Oncology (SGO) is indexed in:
  • SCOPUS
  • EBSCO
  • DOI/Crossref
  • Google Scholar
  • SCImago
  • Harvard Library
  • Open Academic Journals Index (OAJI)

Open Access Statement

Surgery, Gastroenterology and Oncology (SGO) is an open-access, peer-reviewed online journal published by Celsius Publishing House. The journal allows readers to read, download, copy, distribute, print, search, or link to the full text of its articles.

Journal Metrics

Time to first editorial decision: 25 days
Rejection rate: 61%
CiteScore: 0.2



Meetings and Courses in 2025
Meetings and Courses in 2024
Meetings and Courses in 2023
Meetings and Courses in 2022
Meetings and Courses in 2021
Meetings and Courses in 2020
Meetings and Courses in 2019
Verona expert meeting 2019

Creative Commons License
Surgery, Gastroenterology and Oncology applies the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits readers to copy and redistribute the material in any medium or format, remix, adapt, build upon the published works non-commercially, and license the derivative works on different terms, provided the original material is properly cited and the use is non-commercial. Please see: https://creativecommons.org/licenses/by-nc/4.0/
Publisher’s Note:
The opinions, statements, and data contained in article are solely those of the authors and not of Surgery, Gastroenterology and Oncology journal or the editors. Publisher and the editors disclaim responsibility for any damage resulting from any ideas, instructions, methods, or products referred to in the content.